COVID-19 Pneumonia
Conditions
Brief summary
COVID-19 is currently one of the serious public health challenges worldwide, and there is a great need to develop effective treatments. Paxlovid is a Pfizer-developed oral new drug for the treatment of COVID-19. Paxlovid, which is used to treat adult patients with mild to moderate COVID-19 who have high-risk factors for progression to severe disease, was conditionally approved for marketing in the United States and China in December 2021 and February 2022, respectively. Clinical trials have shown that this drug can significantly reduce the progression from mild to severe disease and the rate of hospitalization and mortality. However, due to the limitations of clinical trials in the subject selection, there is still insufficient knowledge about the efficacy and safety of Paxlovid in a real-world population. Relevant studies on this drug in real-world people, especially in Chinese populations, have not been reported. Therefore, this study was designed to investigate the efficacy and safety of Paxlovid on sufferers of COVID-19 through a retrospective, real-world analysis.
Interventions
DRUGstandard-of-care plus Paxlovid
standard-of-care plus Paxlovid
DRUGstandard-of-care
standard-of-care
Sponsors
Ruijin Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with confirmed COVID-19 who had taken more than one dose of Paxlovid.
Exclusion criteria
* Age \< 18 years-old; * Pregnancy; * Data missing \> 20%.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 28-day mortality | 28 days since the diagnosis of COVID-19 | the mortality of the subjects within 28 days since the diagnosis of COVID-19 |
Countries
China
Contacts
Primary ContactJieming Qu, PhD
Outcome results
None listed